Navigation Links
CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
Date:11/19/2007

which coincides with the expansion of our commercial operations into major European markets."

The Medicines Company re-acquired rights to Angiox in Europe in July 2007. Since then, the Company has been expanding its European presence and developing clinical and commercial plans for Angiox with input from European thought leaders in cardiology, thrombosis and health economics. The Company also has been working on clinical trials and expert advisory activities in Europe for the Company's Phase III development compounds, cangrelor and Cleviprex(TM) (clevidipine butyrate injectable emulsion). The Company is creating the legal infrastructure to support operations in Europe, is establishing supply chain capabilities for the territory, and has set up a central office in Zurich, Switzerland. The Medicines Company markets bivalirudin as Angiomax(R) in the United States.

The European Society of Cardiology (ESC) in June 2007 published guidelines for the treatment of ACS that recommend using Angiox in ACS patients undergoing PCI. The Company estimates that more than one million PCI procedures are performed annually in Europe.

The CHMP is the scientific committee of EMEA. The opinions of the CHMP generally serve as the basis for the European Commission approvals, which are valid in all Member States of the European Union and the European Economic Area.

In the United States, a similar Angiomax ACS filing is being reviewed by the U.S. Food and Drug Administration (FDA). The Company expects FDA action in mid-2008.

About ACUITY

ACUITY was one of the largest ACS clinical trials ever conducted to evaluate anti-thrombotic therapies and enrolled 13,819 high-risk patients in 450 centers worldwide. The trial design employed an early invasive strategy (angiography within 72 hours), starting anti-clotting therapy when ACS patients arrived at the emergency department and randomly assigning them to treatment with standard therapy of heparin (unfractionated
'/>"/>

SOURCE The Medicines Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
3. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
4. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
5. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
6. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
7. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
8. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
9. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
10. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
11. BioMosaics Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... Aug. 4, 2015 Among 1,000 U.S. consumers, ... only half of consumers surveyed are aware of prescription ... used use them, according to findings from a new ... service partnership focused on improving the health and well-being ... survey polled 1,000 men and women, ages 21 and ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... financial results for the three month period ended June 30, ... Non-GAAP 1 Highlights: , Revenue ... currency. , North American product sales grew 45% year-over-year. ... constant currency, including 14% product growth in the EMEA region ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 2PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 3PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 4PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 5PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7
(Date:8/4/2015)... ... 04, 2015 , ... Sin City Gallery is delighted to ... diverse group of exceptionally talented female artists. The exhibition premieres at the ... 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura Henkel, ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... without gestational diabetes signals future heart risk, researcher says. , ... given to pregnant women may also show if they have ... new study has found. , This finding is important because ... for gestational diabetes to identify women who are at risk ...
... Aug. 24 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech, Inc. (OTC ... marketer of a variety of cactus-based products in,China, announced ... attend investor conference and meet with U.S. investors in ... roadshow details: , The company ...
... , WASHINGTON, Aug. 24 Secretary of ... (VA) is taking steps to assist Veterans seeking compensation for Post-Traumatic ... of war are being addressed vigorously and comprehensively by this administration ... century," said Secretary Shinseki. , , The VA ...
... , , AUBURN HILLS, ... (OTC Bulletin Board: ECOC), a leader in the discovery ... that it has signed a collaboration agreement with a ... for producing "fire standard compliant" (FSC) cigarettes. FSC cigarettes ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
... , , CINCINNATI and ARDEE, Ireland, Aug. 24, ... Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for ... cash payment of $3.1 billion. , , To view ... m nr/pg/39814/ , , (Logo: ...
Cached Medicine News:Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 2Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 3Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 4Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 6Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 7Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 8
...
... Tupos LV/A+, the single-lead principle has been applied ... The complete system, which consists of the Tupos ... the scope of surgery and the risk of ... and the ventricle via a single lead. The ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis incorporates ... ICD therapy. Cardiac resynchronization benefits include ... pacing outputs to unique patient needs. ... functions that help physicians manage heart ...
Medicine Products: